Pharmaceutical Price Regulation Scheme

(asked on 4th September 2018) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what information his Department holds on how money raised from rebates paid under the Pharmaceutical Price Regulation Scheme 2014 has been used; and if he will make a statement.


Answered by
Steve Brine Portrait
Steve Brine
This question was answered on 12th September 2018

The Department has received £2,328 million from members of the Pharmaceutical Price Regulation Scheme (PPRS), as of Q1 2018, in respect of PPRS payments made under the 2014 scheme. The estimated United Kingdom income from PPRS payments in 2018/19 is £470 million. Published aggregate information on sales reports and payments made under the scheme on a quarterly basis can be found on the Government’s website at the following link:

https://www.gov.uk/government/collections/pprs-quarterly-net-sales-and-payment-information

The Department administers the scheme on behalf of all UK nations and PPRS payments that companies make under the scheme in respect of the UK are allocated to each of the four countries on an agreed basis each year. The Department ensures that all the income it receives from PPRS payments in England is reinvested in the National Health Service for patients’ benefit. The Department includes the expected PPRS payments in setting the NHS England allocations in advance of each year. NHS England is responsible for allocating the overall budget between clinical commissioning groups, specialised commissioning etc.

Following normal Government accounting rules, there is no separately identified or ring-fenced funding stream associated with the PPRS payment. The Government is committed to improving access to clinically and cost-effective medicines including innovative new medicines and to optimise patient outcomes from these medicines.

Reticulating Splines